How targeted cancer drugs affect thinking and memory
Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
['FUNDING_R01'] · H. LEE MOFFITT CANCER CTR & RES INST · NIH-11137786
We will follow people with CML or CLL who are starting tyrosine kinase inhibitor treatment to find out if these targeted drugs change thinking, memory, or attention.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | H. LEE MOFFITT CANCER CTR & RES INST (nih funded) |
| Locations | 1 site (TAMPA, UNITED STATES) |
| Trial ID | NIH-11137786 on ClinicalTrials.gov |
What this research studies
If you join, researchers will enroll people with chronic myeloid leukemia (CML) or chronic lymphocytic leukemia (CLL) before they start a tyrosine kinase inhibitor and follow them over time. You will complete standardized neuropsychological tests (CANTAB) and brief real-time surveys on a smartphone (ecological momentary assessment) to track thinking, memory, and attention. The team will also collect medical and biological information to look for risk factors and possible biological mechanisms. The study will capture both how patients feel about their cognition and how they perform on objective tests.
Who could benefit from this research
Good fit: Adults with chronic myeloid leukemia (CML) or chronic lymphocytic leukemia (CLL) who are about to start treatment with a tyrosine kinase inhibitor are ideal candidates.
Not a fit: People not starting TKIs, those with other cancer types, or whose cognitive issues stem from unrelated causes may not receive direct benefit from this work.
Why it matters
Potential benefit: If successful, the work could help doctors recognize, prevent, or manage thinking and memory problems linked to targeted cancer drugs.
How similar studies have performed: Prior smaller studies and validated tools like CANTAB and EMA support this approach, but large prospective studies of TKIs and cognition are novel.
Where this research is happening
TAMPA, UNITED STATES
- H. LEE MOFFITT CANCER CTR & RES INST — TAMPA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GONZALEZ, BRIAN D — H. LEE MOFFITT CANCER CTR & RES INST
- Study coordinator: GONZALEZ, BRIAN D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.